Reply to ‘Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma’

Teresa AmaralCenter for Dermatooncology, Department of Dermatology, University Hospital Tübingen, Tübingen, Germany;Portuguese Air Force Health Direction, Lisbon, PortugalView further author information

Claus GarbeCenter for Dermatooncology, Department of Dermatology, University Hospital Tübingen, Tübingen, GermanyCorrespondence[email protected]
View further author information

References

Amaral T, Garbe C. Non-melanoma skin cancer: new and future synthetic drug treatments. Expert Opin Pharmacother. 2017;18(7):689–699.
PubMed Web of Science ®Google Scholar
Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–1385.
PubMed Web of Science ®Google Scholar
Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–2552.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Reply to ‘Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma’

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reply to ‘Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma’

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date